Radius Health

$19.40 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Radius Health

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).

Stock Analysis

last close $17.99
1-mo return 47%
3-mo return 6.1%
avg daily vol. 3.44M
52-week high 26.16
52-week low 11.95
market cap. $714M
forward pe -
annual div. -
roe -1449%
ltg forecast -
dividend yield -
annual rev. $249M
inst own. -
baraka

Subscribe now for daily local and international financial news

Subscribe